SCHEMBL4674755

SCHEMBL4674755

O=C(C=C(O)c1nc[nH]n1)c1cc(-c2ccccc2F)co1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.33
CTSA P10619 1/20 0.33
MAOA P21397 1/20 0.33
BLVRB P30043 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
ACMSD Q8TDX5 1/20 0.33
LTB4R Q15722 1/20 0.32
PPARG P37231 1/20 0.31
PPARA Q07869 1/20 0.31
NPC1 O15118 3/20 0.31
RAB9A P51151 3/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
HTT P42858 1/20 0.31
MAPT P10636 2/20 0.31
ALDH1A1 P00352 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KDM4E B2RXH2 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CHRNA4 P43681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675492 0.87 CHRNA4 (0.41) PPARGCHRNA4
SCHEMBL4675030 0.84 CA12 (0.33) MAPTALDH1A1CHRNA4
SCHEMBL4678994 0.83 NR4A1 (0.38) FFAR1CHRNA4
SCHEMBL4676370 0.82 MEN1 (0.34) MAOABLVRBHDAC6NPC1RAB9A
SCHEMBL4675280 0.81 KDM4E (0.46) NPC1RAB9APKMHPGDHTT
SCHEMBL4670907 0.81 BRS3 (0.35) HDAC6RAB9AKDM4E
SCHEMBL4671715 0.78 HTT (0.32) CTSANPC1RAB9APKMHPGD
SCHEMBL4678756 0.78 NPC1 (0.34) NPC1RAB9APKMHPGDHTT
SCHEMBL4679147 0.78 PTGER4 (0.35) L3MBTL1
SCHEMBL4673353 0.78 ALDH1A1 (0.34) FFAR1NPC1RAB9APKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 FFAR1 968/4885CTSA 1589/4885MAOA 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.